Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$13.23 ▼ -0.09
(-0.68%)
MKT CAP: $1.85B • VOL: 4.70M
52W L $8 52W H $18
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$11
MEDIAN
$15
MEAN
$15
HIGH
$18
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NTLA TAPE
NTLA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $16.01 | $15.21 | 2025-02-14 | $12.04 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $16.67 | $15.61 | 2025-02-06 | $12.44 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $15.08 | $14.55 | 2025-01-29 | $12.70 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $13.49 | — | 2025-01-17 | $12.97 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $11.64 | $12.57 | 2025-01-09 | $11.77 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $15.74 | $13.76 | 2024-12-18 | $11.51 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $12.83 | $13.36 | 2024-12-04 | $12.30 | -4.3% | 48% | C |